DPP4-deficient congenic rats display blunted stress, improved fear extinction and increased central NPY

Psychoneuroendocrinology

Volumn 53, Issue , 2015, Pages 195-206

  Canneva, Fabio ^a   Golub, Yulia ^a   Distler, Joerg ^a   Dobner, Julia ^a   Meyer, Sandra ^a   von Hörsten, Stephan ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Anxiety; CD26; DPP4; Fear; NPY; Stress

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; NEUROPEPTIDE Y; DPP4 PROTEIN, RAT; MESSENGER RNA; NEUROPEPTIDE Y RECEPTOR;

ANALGESIA; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLUNTED STRESS; CONCENTRATION (PARAMETERS); CONDITIONING; CONGENIC STRAIN; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEAR; FEMALE; MALE; NONHUMAN; PHENOTYPE; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; RAT; REINFORCEMENT; STRESS; ANIMAL; BRAIN; CONDITIONED REFLEX; DEFICIENCY; GENETICS; METABOLISM; MUTATION; PHYSIOLOGICAL STRESS;

ANIMALS; ANIMALS, CONGENIC; BRAIN; CONDITIONING, CLASSICAL; DIPEPTIDYL PEPTIDASE 4; EXTINCTION, PSYCHOLOGICAL; FEAR; MUTATION; NEUROPEPTIDE Y; RATS; RECEPTORS, NEUROPEPTIDE Y; RNA, MESSENGER; STRESS, PHYSIOLOGICAL;

EID: 84922778434     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.01.007     Document Type: Article

References (72)

1. Abe K., Kuo L., Zukowska Z. Neuropeptide Y is a mediator of chronic vascular and metabolic maladaptations to stress and hypernutrition. Exp. Biol. Med. 2010, 235:1179-1184.
2. Adamcak A., Otten B. Rodent therapeutics. The veterinary clinics of North America. Exot. Anim. Pract. 2000, 3:221-237. viii.
3. Amit Z., Galina Z.H. Stress-induced analgesia: adaptive pain suppression. Physiol. Rev. 1986, 66:1091-1120.
4. Azim S., Baker W.L., White W.B. Evaluating cardiovascular safety of novel therapeutic agents for the treatment of type 2 diabetes mellitus. Curr. Cardiol. Rep. 2014, 16:541.
5. Beck B. Neuropeptide Y in normal eating and in genetic and dietary-induced obesity. Philos. Trans. R. Soc. Lond. B: Biol. Sci. 2006, 361:1159-1185.
6. Bernstein H.G., Schon E., Ansorge S., Rose I., Dorn A. Immunolocalization of dipeptidyl aminopeptidase (DAP IV) in the developing human brain. Int. J. Dev. Neurosci. 1987, 5:237-242.
7. Bisson J.I., Ehlers A., Matthews R., Pilling S., Richards D., Turner S. Psychological treatments for chronic post-traumatic stress disorder. Systematic review and meta-analysis. Br. J. Psychiatry 2007, 190:97-104.
8. Bjelke J.R., Christensen J., Nielsen P.F., Branner S., Kanstrup A.B., Wagtmann N., Rasmussen H.B. Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem. J. 2006, 396:391-399.
9. Boonacker E., Van Noorden C.J. The multifunctional or moonlighting protein CD26/DPPIV. Eur. J. Cell Biol. 2003, 82:53-73.
10. Bradley R., Greene J., Russ E., Dutra L., Westen D. A multidimensional meta-analysis of psychotherapy for PTSD. Am. J. Psychiatry 2005, 162:214-227.
11. Broqua P., Wettstein J.G., Rocher M.N., Gauthier-Martin B., Junien J.L. Behavioral effects of neuropeptide Y receptor agonists in the elevated plus-maze and fear-potentiated startle procedures. Behav. Pharmacol. 1995, 6:215-222.
12. Chen B., Moore A., Escobedo L.V., Koletsky M.S., Hou D., Koletsky R.J., Ernsberger P. Sitagliptin lowers glucagon and improves glucose tolerance in prediabetic obese SHROB rats. Exp. Biol. Med. 2011, 236:309-314.
13. Choy Y., Fyer A.J., Lipsitz J.D. Treatment of specific phobia in adults. Clin. Psychol. Rev. 2007, 27:266-286.
14. Colmers W.F., Bleakman D. Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci. 1994, 17:373-379.
15. Colmers W.F., Lukowiak K., Pittman Q.J. Presynaptic action of neuropeptide Y in area CA1 of the rat hippocampal slice. J. Physiol. 1987, 383:285-299.
16. Corder R., Castagne V., Rivet J.M., Mormede P., Gaillard R.C. Central and peripheral effects of repeated stress and high NaCl diet on neuropeptide Y. Physiol. Behav. 1992, 52:205-210.
17. Drucker D.J. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26:2929-2940.
18. Dubois V., Lambeir A.M., Van der Veken P., Augustyns K., Creemers J., Chen X., Scharpe S., De Meester I. Purification and characterization of dipeptidyl peptidase IV-like enzymes from bovine testes. Front. Biosci. 2008, 13:3558-3568.
19. Fendt M., Burki H., Imobersteg S., Lingenhohl K., McAllister K.H., Orain D., Uzunov D.P., Chaperon F. Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect. Psychopharmacology (Berl) 2009, 206:291-301.
20. Forssmann U., Stoetzer C., Stephan M., Kruschinski C., Skripuletz T., Schade J., Schmiedl A., Pabst R., Wagner L., Hoffmann T., Kehlen A., Escher S.E., Forssmann W.G., Elsner J., von Horsten S. Inhibition of CD26/dipeptidyl peptidase IV enhances CCL11/eotaxin-mediated recruitment of eosinophils in vivo. J. Immunol. 2008, 181:1120-1127.
21. Frerker N., Raber K., Bode F., Skripuletz T., Nave H., Klemann C., Pabst R., Stephan M., Schade J., Brabant G., Wedekind D., Jacobs R., Jorns A., Forssmann U., Straub R.H., Johannes S., Hoffmann T., Wagner L., Demuth H.U., von Horsten S. Phenotyping of congenic dipeptidyl peptidase 4 (DP4) deficient Dark Agouti (DA) rats suggests involvement of DP4 in neuro-, endocrine, and immune functions. Clin. Chem. Lab. Med. 2009, 47:275-287.
22. Fuhlendorff J., Gether U., Aakerlund L., Langeland-Johansen N., Thogersen H., Melberg S.G., Olsen U.B., Thastrup O., Schwartz T.W. [Leu31, Pro34]neuropeptide Y: a specific Y1 receptor agonist. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:182-186.
23. Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update). Drugs Today 2007, 43:801-814.
24. Giesbrecht C.J., Mackay J.P., Silveira H.B., Urban J.H., Colmers W.F. Countervailing modulation of Ih by neuropeptide Y and corticotrophin-releasing factor in basolateral amygdala as a possible mechanism for their effects on stress-related behaviors. J. Neurosci. 2010, 30:16970-16982.
25. Golub Y., Kaltwasser S.F., Mauch C.P., Herrmann L., Schmidt U., Holsboer F., Czisch M., Wotjak C.T. Reduced hippocampus volume in the mouse model of Posttraumatic Stress Disorder. J. Psychiatr. Res. 2011, 45:650-659.
26. Gutman A.R., Yang Y., Ressler K.J., Davis M. The role of neuropeptide Y in the expression and extinction of fear-potentiated startle. J. Neurosci. 2008, 28:12682-12690.
27. Hall J., Thomas K.L., Everitt B.J. Fear memory retrieval induces CREB phosphorylation and Fos expression within the amygdala. Eur. J. Neurosci. 2001, 13:1453-1458.
28. Hartel S., Gossrau R., Hanski C., Reutter W. Dipeptidyl peptidase (DPP) IV in rat organs. Comparison of immunohistochemistry and activity histochemistry. Histochemistry 1988, 89:151-161.
29. Heffner T.G., Hartman J.A., Seiden L.S. A rapid method for the regional dissection of the rat brain. Pharmacol. Biochem. Behav. 1980, 13:453-456.
30. Heilig M. The NPY system in stress, anxiety and depression. Neuropeptides 2004, 38:213-224.
31. Heilig M., Soderpalm B., Engel J.A., Widerlov E. Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models. Psychopharmacology (Berl) 1989, 98:524-529.
32. Heilig M., Zachrisson O., Thorsell A., Ehnvall A., Mottagui-Tabar S., Sjogren M., Asberg M., Ekman R., Wahlestedt C., Agren H. Decreased cerebrospinal fluid neuropeptide Y (NPY) in patients with treatment refractory unipolar major depression: preliminary evidence for association with preproNPY gene polymorphism. J. Psychiatr. Res. 2004, 38:113-121.
33. Kamprath K., Marsicano G., Tang J., Monory K., Bisogno T., Di Marzo V., Lutz B., Wotjak C.T. Cannabinoid CB1 receptor mediates fear extinction via habituation-like processes. J. Neurosci. 2006, 26:6677-6686.
34. Karl T., Chwalisz W.T., Wedekind D., Hedrich H.J., Hoffmann T., Jacobs R., Pabst R., von Horsten S. Localization, transmission, spontaneous mutations, and variation of function of the Dpp4 (Dipeptidyl-peptidase IV; CD26) gene in rats. Regul. Pept. 2003, 115:81-90.
35. Karl T., Hoffmann T., Pabst R., von Horsten S. Behavioral effects of neuropeptide Y in F344 rat substrains with a reduced dipeptidyl-peptidase IV activity. Pharmacol. Biochem. Behav. 2003, 75:869-879.
36. Karl T., Hoffmann T., Pabst R., von Horsten S. Extreme reduction of dipeptidyl peptidase IV activity in F344 rat substrains is associated with various behavioral differences. Physiol. Behav. 2003, 80:123-134.
37. Kask A., Harro J., von Horsten S., Redrobe J.P., Dumont Y., Quirion R. The neurocircuitry and receptor subtypes mediating anxiolytic-like effects of neuropeptide Y. Neurosci. Biobehav. Rev. 2002, 26:259-283.
38. Kastin A.J., Akerstrom V. Nonsaturable entry of neuropeptide Y into brain. Am. J. Physiol. 1999, 276:E479-E482.
39. King P.J., Widdowson P.S., Doods H.N., Williams G. Regulation of neuropeptide Y release by neuropeptide Y receptor ligands and calcium channel antagonists in hypothalamic slices. J. Neurochem. 1999, 73:641-646.
40. King P.J., Williams G., Doods H., Widdowson P.S. Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release. Eur. J. Pharmacol. 2000, 396:R1-R3.
41. Kuo L.E., Abe K., Zukowska Z. Stress, NPY and vascular remodeling: implications for stress-related diseases. Peptides 2007, 28:435-440.
42. Kuo L.E., Kitlinska J.B., Tilan J.U., Li L., Baker S.B., Johnson M.D., Lee E.W., Burnett M.S., Fricke S.T., Kvetnansky R., Herzog H., Zukowska Z. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat. Med. 2007, 13:803-811.
43. Lundberg J.M., Tatemoto K. Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol. Scand. 1982, 116:393-402.
44. Lundberg J.M., Terenius L., Hokfelt T., Martling C.R., Tatemoto K., Mutt V., Polak J., Bloom S., Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol. Scand. 1982, 116:477-480.
45. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul. Pept. 1999, 85:9-24.
46. Mentlein R. Cell-surface peptidases. Int. Rev. Cytol. 2004, 235:165-213.
47. Mitro A., Lojda Z. Histochemistry of proteases in ependyma, choroid plexus and leptomeninges. Histochemistry 1988, 88:645-646.
48. Morgan C.A., Rasmusson A.M., Wang S., Hoyt G., Hauger R.L., Hazlett G. Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol. Psychiatry 2002, 52:136-142.
49. Morgan C.A., Rasmusson A.M., Winters B., Hauger R.L., Morgan J., Hazlett G., Southwick S. Trauma exposure rather than posttraumatic stress disorder is associated with reduced baseline plasma neuropeptide-Y levels. Biol. Psychiatry 2003, 54:1087-1091.
50. Morgan C.A., Wang S., Southwick S.M., Rasmusson A., Hazlett G., Hauger R.L., Charney D.S. Plasma neuropeptide-Y concentrations in humans exposed to military survival training. Biol. Psychiatry 2000, 47:902-909.
51. Myers A.K., Farhat M.Y., Vaz C.A., Keiser H.R., Zukowska-Grojec Z. Release of immunoreactive-neuropeptide by rat platelets. Biochem. Biophys. Res. Commun. 1988, 155:118-122.
52. Ogawa T., Kitamura K., Kawamoto M., Eto T., Tanaka K. Increased immunoreactive neuropeptide Y in platelets of spontaneously hypertensive rats (SHR). Biochem. Biophys. Res. Commun. 1989, 165:1399-1405.
53. Pegg C.C., He C., Stroink A.R., Kattner K.A., Wang C.X. Technique for collection of cerebrospinal fluid from the cisterna magna in rat. J. Neurosci. Methods 2010, 187:8-12.
54. Pickens C.L., Adams-Deutsch T., Nair S.G., Navarre B.M., Heilig M., Shaham Y. Effect of pharmacological manipulations of neuropeptide Y and corticotropin-releasing factor neurotransmission on incubation of conditioned fear. Neuroscience 2009, 164:1398-1406.
55. Pitman R.K., Rasmusson A.M., Koenen K.C., Shin L.M., Orr S.P., Gilbertson M.W., Milad M.R., Liberzon I. Biological studies of post-traumatic stress disorder. Nat. Rev. Neurosci. 2012, 13:769-787.
56. Plendl W., Wotjak C.T. Dissociation of within- and between-session extinction of conditioned fear. J. Neurosci. 2010, 30:4990-4998.
57. Qian J., Colmers W.F., Saggau P. Inhibition of synaptic transmission by neuropeptide Y in rat hippocampal area CA1: modulation of presynaptic Ca2+ entry. J. Neurosci. 1997, 17:8169-8177.
58. Rasmusson A.M., Hauger R.L., Morgan C.A., Bremner J.D., Charney D.S., Southwick S.M. Low baseline and yohimbine-stimulated plasma neuropeptide Y (NPY) levels in combat-related PTSD. Biol. Psychiatry 2000, 47:526-539.
59. Rasmusson A.M., Schnurr P.P., Zukowska Z., Scioli E., Forman D.E. Adaptation to extreme stress: post-traumatic stress disorder, neuropeptide Y and metabolic syndrome. Exp. Biol. Med. 2010, 235:1150-1162.
60. Sah R., Ekhator N.N., Strawn J.R., Sallee F.R., Baker D.G., Horn P.S., Geracioti T.D. Low cerebrospinal fluid neuropeptide Y concentrations in posttraumatic stress disorder. Biol. Psychiatry 2009, 66:705-707.
61. Sajdyk T.J., Vandergriff M.G., Gehlert D.R. Amygdalar neuropeptide Y Y1 receptors mediate the anxiolytic-like actions of neuropeptide Y in the social interaction test. Eur. J. Pharmacol. 1999, 368:143-147.
62. Sauerhofer E., Pamplona F.A., Bedenk B., Moll G.H., Dawirs R.R., von Horsten S., Wotjak C.T., Golub Y. Generalization of contextual fear depends on associative rather than non-associative memory components. Behav. Brain Res. 2012, 233:483-493.
63. Serova L.I., Laukova M., Alaluf L.G., Pucillo L., Sabban E.L. Intranasal neuropeptide Y reverses anxiety and depressive-like behavior impaired by single prolonged stress PTSD model. Eur. Neuropsychopharmacol. 2014, 24:142-147.
64. Serova L.I., Tillinger A., Alaluf L.G., Laukova M., Keegan K., Sabban E.L. Single intranasal neuropeptide Y infusion attenuates development of PTSD-like symptoms to traumatic stress in rats. Neuroscience 2013, 236:298-312.
65. Siegmund A., Wotjak C.T. Toward an animal model of posttraumatic stress disorder. Ann. N. Y. Acad. Sci. 2006, 1071:324-334.
66. Stephan M., Radicke A., Leutloff S., Schmiedl A., Pabst R., von Horsten S., Dettmer S., Lotz J., Nave H. Dipeptidyl peptidase IV (DPP4)-deficiency attenuates diet-induced obesity in rats: possible implications for the hypothalamic neuropeptidergic system. Behav. Brain Res. 2011, 216:712-718.
67. Stephan M., Suhling H., Schade J., Wittlake M., Tasic T., Klemann C., Pabst R., Jurawitz M.C., Raber K.A., Hoymann H.G., Braun A., Glaab T., Hoffmann T., Schmiedl A., von Horsten S. Effects of dipeptidyl peptidase-4 inhibition in an animal model of experimental asthma: a matter of dose, route, and time. Physiol. Rep. 2013, 1:e00095.
68. Thorsell A., Carlsson K., Ekman R., Heilig M. Behavioral and endocrine adaptation, and up-regulation of NPY expression in rat amygdala following repeated restraint stress. Neuroreport 1999, 10:3003-3007.
69. Verma D., Tasan R.O., Herzog H., Sperk G. NPY controls fear conditioning and fear extinction by combined action on Y(1) and Y(2) receptors. Br. J. Pharmacol. 2012, 166:1461-1473.
70. von Horsten S., Helfritz A., Kuhlmann S., Nave H., Tschernig T., Pabst R., Ben-Eliyahu S., Meyer D., Schmidt R.E., Schmitz C. Stereological quantification of carboxyfluorescein-labeled rat lung metastasis: a new method for the assessment of natural killer cell activity and tumor adhesion in vivo and in situ. J. Immunol. Methods 2000, 239:25-34.
71. Yehuda R., Brand S., Yang R.K. Plasma neuropeptide Y concentrations in combat exposed veterans: relationship to trauma exposure, recovery from PTSD, and coping. Biol. Psychiatry 2006, 59:660-663.
72. Zhou Z., Zhu G., Hariri A.R., Enoch M.A., Scott D., Sinha R., Virkkunen M., Mash D.C., Lipsky R.H., Hu X.Z., Hodgkinson C.A., Xu K., Buzas B., Yuan Q., Shen P.H., Ferrell R.E., Manuck S.B., Brown S.M., Hauger R.L., Stohler C.S., Zubieta J.K., Goldman D. Genetic variation in human NPY expression affects stress response and emotion. Nature 2008, 452:997-1001.